Trophos SA, of Marseille, France, said that it received a European Union award of €6 million (US$8 million) to support MitoCare, a two-and-a-half year international, translational medicine project that will begin in January 2011 and will be conducted by a 16-partner consortium led by Trophos. MitoCare will investigate the efficacy and safety of TRO40303 in a Phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury in acute myocardial infarction patients and develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury, the company said.